Anthropic has pulled the trigger on a $400 million all-stock acquisition of Coefficient Bio, a stealth-mode biotech startup founded less than a year ago by two former Genentech researchers. The deal marks Anthropic's most aggressive move yet into biotech and signals an escalating wager that Claude can fundamentally reshape how pharmaceutical companies discover and develop drugs.
The acquisition brings fewer than 10 people into Anthropic's fold, all computational biologists with deep expertise in drug design. Coefficient Bio's co-founders, Samuel Stanton and Nathan C. Frey, both spent years at Genentech's Prescient Design unit developing AI models for molecular design. Their platform uses AI for drug R&D planning, clinical regulatory strategy, and novel drug candidate identification.
"We want a meaningful percentage of all of the life science work in the world to run on Claude"
We want a meaningful percentage of all of the life science work in the world to run on Claude, said Eric Kauderer-Abrams, who leads Anthropic's Healthcare and Life Sciences group.
Coefficient Bio was founded just eight months before the acquisition. Its backer Dimension Ventures will reportedly see a 38,513% internal rate of return. At Anthropic's $380 billion valuation, the $400 million purchase represents roughly 0.1% dilution — chump change for a company approaching a potential IPO.
The acquisition is Anthropic's third known deal, following Bun and Vercept, but the first to so visibly straddle enterprise AI and biotech.